Bos, M. K. http://orcid.org/0000-0002-2984-7542
Lam, S. W.
Motta, G.
Helmijr, J. C. A.
Beaufort, C. M.
de Jonge, E.
Martens, J. W. M.
Boven, E.
Jansen, M. P. H. M.
Jager, A.
Sleijfer, S.
Funding for this research was provided by:
KWF Kankerbestrijding (NKB-EMCR-2016-108154)
Article History
Received: 16 December 2022
Accepted: 2 May 2023
First Online: 25 May 2023
Declarations
:
: M.K. Bos received research funding from Dutch Cancer Society (no. NKB-EMCR-2016–108154), S.W. Lam: none, G. Motta: none, J.C.A. Helmijr: none, C.M. Beaufort: none, E. de Jonge: none, J.W.M. Martens received sponsorship for research from Pfizer, Menarini, GSK Cytotrack, Cergentis, payment for consultancy from Novartis, and payment for presentation from Roche, E. Boven: none, M.P.H.M. Jansen: none, A. Jager: none, and S. Sleijfer: none.<b>Ethical approval and consent to participate</b>The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of all participating centers. Written informed consent was obtained before study enrollment. This trial is registered with the European Union Drug Regulating Authorities Clinical Trials, number 2006–006058-83, and the Netherlands Trial Register, number NTR1348.
: Not applicable.